Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.
Read More
Successful treatment of RPE65-mediated inherited retinal dystrophy with voretigene neparvovec
January 31st 2025Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.
Read More
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.
Read More